Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245962 | 1.00 | PKM (0.46) | PKMCA1CA2CA12CA4 | |
| SCHEMBL30267353 | 0.87 | ALDH1A1 (0.47) | PKMMAPTALDH1A1CYP2C19MMP2 | |
| SCHEMBL15152645 | 0.85 | L3MBTL1 (0.47) | PKMCA1CA2CA4CA7 | |
| SCHEMBL15152644 | 0.85 | L3MBTL1 (0.47) | PKMCA1CA2CA4CA7 | |
| SCHEMBL14345167 | 0.83 | PKM (0.44) | PKMCA1CA2CA12CA4 | |
| SCHEMBL13245959 | 0.82 | MAPT (0.62) | PKMCA1CA2F2PRSS1 | |
| SCHEMBL2993765 | 0.82 | MAPT (0.62) | PKMCA1CA2F2PRSS1 | |
| SCHEMBL2149410 | 0.80 | TSHR (0.52) | PKMCA1CA2CA12CA4 | |
| SCHEMBL13245960 | 0.80 | KDM4E (0.44) | PKMTSHRSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2986017 | 0.80 | KDM4E (0.44) | PKMTSHRSMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| EP-2032547-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007141545-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173958-A1 | COMPOUNDS FOR THE INHIBITION OF DGAT1 ACTIVITY | DGAT1, DGAT2, ACAT2 | PKM 2371/4885CA1 2971/4885CA2 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.